Teva Pharmaceutical Industries (Teva Pharmaceutical Industries) Risk Assessment

View and export this data going back to 1990. Start your Free Trial

What is Teva Pharmaceutical Industries Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Teva Pharmaceutical Industries is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of Teva Pharmaceutical Industries's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Teva Pharmaceutical Industries's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Teva Pharmaceutical Industries's Risk Assessment falls into.

Teva Pharmaceutical Industries (NYSE:TEVA) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Teva Pharmaceutical Industries Risk Assessment Related Terms

Thank you for viewing the detailed overview of Teva Pharmaceutical Industries's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Teva Pharmaceutical Industries (Teva Pharmaceutical Industries) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teva Pharmaceutical Industries Ltd (NYSE:TEVA) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

TEVJF:USA TEVA:Mexico TEVA:Israel 0LER:UK TEV:Germany TEV:Germany TEV:Germany T1EV34:Brazil TEVA:Austria

Address

124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020

Website

https://www.tevapharm.com

Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.

Executives

Dov Bergwerk	officer: Acting Chief Legal Officer	C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Vikki L Conway	officer: See "Remarks"	C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Varda Shalev	director	MATAM PARK, BUILDING #5, HAIFA L3 3508409
Eliyahu Sharon Kalif	officer: EVP, Chief Financial Officer	C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Amir Weiss	officer: Chief Accounting Officer	C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Angus Grant	officer: EVP, Business Development	C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Eric A Hughes	officer: See "Remarks"	C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Sven Dethlefs	officer: EVP Global Marketing&Portfolio	5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Eric Drape	officer: Executive VP Global Operations	C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
David Matthew Stark	officer: Exec. VP Chief Legal Officer	5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Richard Daniell	officer: Exec. VP, European Commercial	5 BASEL STREET, PO BOX 3190, PETACH TIKVA L3 4951033
Richard D Francis	officer: President and CEO	IM LANGACHER 44, GREIFENSEE V8 8606
Hafrun Fridriksdottir	officer: Executive VP, Global R&D	400 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Eli Shani	officer: EVP,Global Marketing&Portfolio	C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Tal Zvi Zaks	director	C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX